Rinkoo Dalan’s Post

📅 Save the Date: Join LifeSci Events and Disc Medicine for a virtual "Lunch with LifeSci" event on September 14th at 1:00 PM EDT! Disc Medicine is a clinical-stage #biotech company pioneering groundbreaking treatments for rare #BloodDiseases, erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), affecting 8,000 people in the US and Europe. 💡 What to Expect: 👉 Gain insights into Disc Medicine's transformative drug, Bitopertin, designed to alleviate extreme pain and skin damage triggered by sunlight exposure in EPP and XLP patients. 👉 Learn about Bitopertin's impressive 40% reduction in toxic byproduct PPIX, leading to enhanced quality of life and a 96% decrease in phototoxic reactions. 👉 Get a sneak peek into Disc Medicine's upcoming Phase 2 trial results for AURORA, promising even more progress. 👉 Explore Disc's second asset, DISC-0974, with potential applications in anemias associated with inflammatory diseases. 👉 Hear from John Quisel about the company's future and its exciting potential in the world of blood diseases. Reserve your seat: https://lnkd.in/e8vVmhB3 #LifeSciEvent #LifeSciences

Can Understanding HO-1 in BACH1 Knockout Mice Help Treat Sepsis Better? Raghavan Pillai Raju, Medical College of Georgia at Augusta University, USA, will present a short oral contribution during #RedoxMedicine2024 elaborating on this topic. Dr. Raju will discuss  the regulation of HO-1 in BACH1 knockout mice following sepsis. He will provide new insights into the regulatory mechanisms of HO-1 in response to sepsis, potentially informing new therapeutic strategies. Join us on June 27-28, 2024 at Fondation Biermans-Lapôtre, Paris, to learn more! 🔗 Selected Short Orals: https://lnkd.in/gypa9uFD. 🌐 More information: https://lnkd.in/dkNzFQZU. #RedoxMedicieSociety #RedoxMedicine2024 #biomarkers #redoxbiology #redox #antioxidants #innovation #oxidativestress #RedoxResearch

💡 Pioneering Pressure Ulcer Management! 💡 Dr. Thomas Serena’s recently published study continues to show BLASTX breakthroughs in pressure ulcer (PU) management. This cutting-edge approach integrates biofilm-disrupting agent alongside negative pressure wound therapy (NPWT), showcasing great efficacy in accelerating healing and transforming outcomes. 🔍 Key Insights: Involving 20 patients with stubborn PUs resistant to traditional NPWT, 45% of patients saw a significant reduction in PU size by week 4, and in ALL cases rapid disappearance of bacterial fluorescence in the wound beds. Delve into how this pioneering combination therapy addresses bacterial burden and improved healing outcomes: https://lnkd.in/dZpS8JMN To read the parent study: https://lnkd.in/dTsgbkKV #PressureUlcerManagement #InnovativeTherapies #BiofilmDisruption #NPWT #BLASTX #WoundHealing #ClinicalAdvancements #PatientCare #nextscience

Astellas Pharma licences Eko Health digital stethoscope as part of Heart Failure Digital Therapeutic (DTx)>> 🩺Astellas has licensed rights to a smart stethoscope device, the CORE 500, from Eko Health, as part of a digital therapeutic (DTx) strategy for heart failure 🩺The CORE 500, combined with artificial intelligence algorithms, detects and diagnoses cardiovascular disease, aiding in the treatment and management of heart failure 🩺This device will be combined with a digital health platform developed by Welldoc allowing for connection between patients, healthcare teams, and health systems 🩺The combined product, Z1608, will remotely monitor physiological biomarkers linked to heart failure, offering coaching on diet, activity, and medication adherence, using content provided by the American Heart Association 🩺The goal is to demonstrate that Z1608 can reduce acute decompensation events in heart failure patients and secure FDA approval for this application 🩺Last year, Eko received FDA approval for the CORE 500 device and its accompanying AI algorithm, capable of detecting cardiovascular abnormalities with an accuracy of 80-90% 👇Link to article below in comments #AI #Pharma #DigitalHealth

iTestis, led by Ass/Prof Ben Tran in collaboration with WEHI, is revolutionising clinical data collection for GCT patients in Australia. It provides a comprehensive solution to the challenges of data collection and analysis in the treatment of germ cell tumours. By collecting high-quality clinical data and linking it with biological specimens, iTestis describes the current practice patterns of Australian clinicians and engages in retrospective research projects and translational studies. It also serves as a platform for registry-based clinical trials. Powered by BioGrid's secure platform, iTestis is setting new standards in GCT patient care. Read more - https://loom.ly/Wy_eCJA

NEW Trial in Focus: PIMMs – a decentralized trial of #ivosidenib in CCUS 🔍🩸 In this new & exclusive feature, leading #hemonc expert Kelly Bolton, Washington University School of Medicine in St. Louis, discusses the rationale, design & aims of the #PIMMstrial investigating the use of #ivosidenib in patients with CCUS and mutations in #IDH1 🔬 Clonal cytopenia of undetermined significance (CCUS) is a condition characterized by #clonalhematopoiesis (CH) and #cytopenia, and it significantly increases the risk of developing #acutemyeloidleukemia (#AML) and #myelodysplasticsyndromes (#MDS) The Preventing IDH Mutant Myeloid Neoplasm (PIMMs; NCT05030441) #clinicaltrial is the first of its kind and will investigate the #safety and #efficacy of a drug called #ivosidenib in patients with CCUS. This trial aims to determine whether #ivosidenib is effective in preventing the progression of CCUS and later development of #myeloidneoplasms 💡 Within this multi-media feature, we cover: ⭐ Rationale For Using #Ivosidenib In Earlier Disease Stages ⭐ The Unique Design Of The PIMMs Trial ⭐ The Potential Impact Of The PIMMs Trial & Future Steps Take a look 👉 https://lnkd.in/djTey6kW #HemOnc #ClinicalTrials #MDSsm #AMLsm #Leusm

Live from #ESCCongress 2023: BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk Nicola Ryan reviews this randomized, open-label clinical trial that once again confirms that 1-month #DAPT is confirmed is safe in high-bleeding risk patients https://lnkd.in/d8rRk4fQ #interventionalcardiology

📚 [#article] [#BPEnews] Université de Bordeaux 🎉 Congratulations to the BPE Team project for this new publication about the identification of venous thromboembolism (VTE) in the French National Healthcare Database. 🔐 What are the key points? - Identification of VTE is possible in the French National healthcare database with a 92% positive predictive value. - Re-identification of patients in the French National Healthcare database is forbidden, making it impossible to conduct classical validation studies. - Anonymized patient profiles reconstituted from claims data are relevant materials to conduct intra-database case adjudication, in the absence of an alternative. - The presence of a clearly identifiable care sequence around the event to be validated is essential to the success of an intra-database validation study. - Feedback from experts following the validation of cases is an important element for improving case-validation algorithms. 👏 Nicolas Thurin - Angela Grelaud-Boussinot - Adeline Grolleau - Marie-Agnès BERNARD - Emmanuelle Bignon - Patrick Blin - Régis Lassalle - Cécile Droz-Perroteau

We are excited to have presented data at the #RareDiseaseDay2024 Symposium, CDG Scientific and Family Conference showing encouraging efficacy from our ongoing #clinicaltrial of GLM101 in #PMM2CDG.  Read the press release here:  https://lnkd.in/gJuXvR79 #CDGresearch #rarediseases #raredisease #clinicaltrials #RareDiseaseDay

NEW from #ASH2023 | #Belantamab #mafodotin combined with #lenalidomide and #dexamethasone in #RRMM: insights from DREAMM-6 🎥 Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, presents findings from the Phase I DREAMM-6 trial (NCT03544281), evaluating the #BCMA-targeting #antibodydrugconjugate #belantamabmafodotin (belamaf) in combination with #lenalidomide and #dexamethasone in patients with #relapsed/#refractory #multiplemyeloma (RRMM)🩸 The trial establishes a recommended #lenalidomide dose of 25mg for future trials and demonstrates that a lower belamaf dose is better tolerated and more feasible💡 Give it a watch to learn more 👉 https://lnkd.in/davCzA_a #HemOnc